Can a rheumatoid arthritis drug ease Sjögren's symptoms?
NCT ID NCT01782235
First seen Jan 27, 2026 · Last updated May 13, 2026 · Updated 19 times
Summary
This study tested a drug called tocilizumab in 110 adults with primary Sjögren's syndrome, an autoimmune disease that causes dry eyes, dry mouth, pain, and fatigue. Tocilizumab blocks a protein (IL-6) that fuels inflammation. The goal was to see if it could reduce disease activity without causing serious side effects. Results may show whether this drug offers a new treatment option for managing symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY SJÖGREN'S SYNDROME (PSS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hôpitaux Universitaires de Strasbourg
Strasbourg, 67098, France
Conditions
Explore the condition pages connected to this study.